BACKGROUND: Chronic idiopathic enteropathies (CIE) in dogs are complex diseases of unknown origin. AST-120 is a spherical carbon adsorbent preparation with a high adsorption ability for low molecular substances. OBJECTIVES: Evaluation of the clinical efficacy of AST-120 in dogs with CIE. ANIMALS: Ten client-owned dogs with mild (n = 7) to moderate (n = 3) CIE. METHODS: Explorative, prospective, randomized, placebo-controlled, double-blinded pilot study. Dogs with chronic diarrhea and no or insufficient response to an elimination diet were included. The dogs received either AST-120 (n = 5) or placebo (n = 5) for a duration of 21 days. The canine inflammatory bowel disease activity index (CIBDAI) was used to assess disease severity at baseline and clinical outcome after 3 weeks of treatment. Furthermore, changes in body weight and the parameters stool consistency and frequency were compared within and between groups. RESULTS: The mean CIBDAI score decreased from 5.6 (SD 1.5) to 2.0 (SD 1.2) in the AST-120 group (P = .125) and from 4.8 (SD .8) to 3.6 (SD 2.3) in the placebo group (P = .688). Compared with baseline, posttreatment CIBDAI scores decreased more than 60% in 4/5 dogs treated with AST-120 and in 1/5 dogs treated with placebo (P = .206). Changes in CIBDAI scores, body weights, stool consistency, and frequency within and between groups did not achieve statistical significance after 3 weeks of treatment. No adverse effects of AST-120 were noted. CONCLUSIONS AND CLINICAL IMPORTANCE: This study investigated potential efficacy of AST-120 as an alternative therapy in dogs with mild-to-moderate CIE.
BACKGROUND:Chronic idiopathic enteropathies (CIE) in dogs are complex diseases of unknown origin. AST-120 is a spherical carbon adsorbent preparation with a high adsorption ability for low molecular substances. OBJECTIVES: Evaluation of the clinical efficacy of AST-120 in dogs with CIE. ANIMALS: Ten client-owned dogs with mild (n = 7) to moderate (n = 3) CIE. METHODS: Explorative, prospective, randomized, placebo-controlled, double-blinded pilot study. Dogs with chronic diarrhea and no or insufficient response to an elimination diet were included. The dogs received either AST-120 (n = 5) or placebo (n = 5) for a duration of 21 days. The canineinflammatory bowel disease activity index (CIBDAI) was used to assess disease severity at baseline and clinical outcome after 3 weeks of treatment. Furthermore, changes in body weight and the parameters stool consistency and frequency were compared within and between groups. RESULTS: The mean CIBDAI score decreased from 5.6 (SD 1.5) to 2.0 (SD 1.2) in the AST-120 group (P = .125) and from 4.8 (SD .8) to 3.6 (SD 2.3) in the placebo group (P = .688). Compared with baseline, posttreatment CIBDAI scores decreased more than 60% in 4/5 dogs treated with AST-120 and in 1/5 dogs treated with placebo (P = .206). Changes in CIBDAI scores, body weights, stool consistency, and frequency within and between groups did not achieve statistical significance after 3 weeks of treatment. No adverse effects of AST-120 were noted. CONCLUSIONS AND CLINICAL IMPORTANCE: This study investigated potential efficacy of AST-120 as an alternative therapy in dogs with mild-to-moderate CIE.
Authors: Sergi Segarra; Silvia Martínez-Subiela; Marta Cerdà-Cuéllar; Daniel Martínez-Puig; Alberto Muñoz-Prieto; Fernando Rodríguez-Franco; Antonio Rodríguez-Bertos; Karin Allenspach; Alfonso Velasco; José Cerón Journal: BMC Vet Res Date: 2016-03-10 Impact factor: 2.741
Authors: Rodrigo Otávio Silveira Silva; Carlos Augusto de Oliveira Júnior; Dominique S Blanc; Silvia Trindade Pereira; Mário Cesar Rennó de Araujo; Artur Vasconcelos; Francisco Carlos Faria Lobato Journal: Anaerobe Date: 2018-04-03 Impact factor: 3.331